Symptomatic Cognitive Enhancing Agents

Developing Therapeutics for Alzheimer's Disease: Progress and Challenges

Volumn , Issue , 2016, Pages 459-475

  Cummings, J L ^a   Zhong, K ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Lou Ruvo Center for Brain Health   (United States)

Author keywords

5 HT6 antagonist; Alzheimer's disease; Biomarker; Cholinesterase inhibitor; Cognitive enhancement; Donepezil; Emerging therapy; Memantine; Nicotinic agonist; Rivastigmine

Indexed keywords

EID: 85011796844     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-802173-6.00017-4     Document Type: Chapter

References (83)

1. Amacher D.E. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol Appl Pharmacol 2010, 245:134-142.
2. Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 2009, 118:167-179.
3. Aso E., Ferrer I. Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Front Pharmacol 2014, 5:37.
4. Aso E., Palomer E., Juves S., et al. CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AbetaPP/PS1 mice. J Alzheimers Dis 2012, 30:439-459.
5. Assis D.N., Navarro V.J. Human drug hepatotoxicity: a contemporary clinical perspective. Expert Opin Drug Metab Toxicol 2009, 5:463-473.
6. Atri A., Molinuevo J.L., Lemming O., et al. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther 2013, 5:6.
7. Bansal Y., Silakari O. Multifunctional compounds: smart molecules for multifactorial diseases. Eur J Med Chem 2014, 76:31-42.
8. Bateman R.J., Munsell L.Y., Morris J.C., et al. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006, 12:856-861.
9. Bentwich J., Dobronevsky E., Aichenbaum S., et al. Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease: a proof of concept study. J Neural Transm 2011, 118:463-471.
10. Bharadwaj P.R., Bates K.A., Porter T., et al. Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases. Transl Psychiatr 2013, 3:e332.
11. Claxton A., Baker L.D., Hanson A., et al. Long-acting intranasal insulin Detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J Alzheimers Dis 2014, 44:897-906.
12. Cummings J.L., Mega M., Gray K., et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308-2314.
13. Cummings J.L., Froelich L., Black S.E., et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10cm(2)) in Alzheimer's disease. Dement Geriatr Cogn Disord 2012, 33:341-353.
14. Cummings J.L., Morstorf T., Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 2014, 6:37.
15. Da Costa B.E., Becker G., Bouteiller C., et al. Radiosynthesis and in vivo evaluation of fluorinated huprine derivates as PET radiotracers of acetylcholinesterase. Nucl Med Biol 2013, 40:554-560.
16. Davis K.L., Thal L.J., Gamzu E.R., et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease: the Tacrine Collaborative Study Group. N Engl J Med 1992, 327:1253-1259.
17. de Bruin N.M., Prickaerts J., Lange J.H., et al. SLV330, a cannabinoid CB1 receptor antagonist, ameliorates deficits in the T-maze, object recognition and social recognition tasks in rodents. Neurobiol Learn Mem 2010, 93:522-531.
18. Deardorff W.J., Shobassy A., Grossberg G.T. Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication. Expert Rev Neurother 2015, 15:7-17.
19. Devan B.D., Pistell P.J., Duffy K.B., et al. Phosphodiesterase inhibition facilitates cognitive restoration in rodent models of age-related memory decline. NeuroRehabilitation 2014, 34:101-111.
20. Dineley K.T., Jahrling J.B., Denner L. Insulin resistance in Alzheimer's disease. Neurobiol Dis 2014, 72PA:92-103.
21. Dubois B., Feldman H.H., Jacova C., et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014, 13:614-629.
22. Emre M., Aarsland D., Albanese A., et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004, 351:2509-2518.
23. Farlow M., Gracon S.I., Hershey L.A., et al. A controlled trial of tacrine in Alzheimer's disease: the Tacrine Study Group. J Amer Med Assoc 1992, 268:2523-2529.
24. Farlow M.R., Salloway S., Tariot P.N., et al. Effectiveness and tolerability of high-dose (23mg/d) versus standard-dose (10mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 2010, 32:1234-1251.
25. Ferri N., Siegl P., Corsini A., et al. Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacol Ther 2013, 138:470-484.
26. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
27. Freiherr J., Hallschmid M., Frey W.H., et al. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 2013, 27:505-514.
28. Galasko D., Bennett D., Sano M., et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997, 11(Suppl 2):S33-S39.
29. Garcia-Barroso C., Ugarte A., Martinez M., et al. Phosphodiesterase inhibition in cognitive decline. J Alzheimers Dis 2014, 42(Suppl 4):S561-S573.
30. Gonzalez-Lima F., Barksdale B.R., Rojas J.C. Mitochondrial respiration as a target for neuroprotection and cognitive enhancement. Biochem Pharmacol 2014, 88:584-593.
31. Grove R.A., Harrington C.M., Mahler A., et al. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. Curr Alzheimer Res 2014, 11:47-58.
32. Gurney M.E., D'Amato E.C., Burgin A.B. Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease. Neurotherapeutics 2014, 12:49-56.
33. Haig G.M., Pritchett Y., Meier A., et al. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia. J Alzheimers Dis 2014, 42:959-971.
34. Harrison J., Minassian S.L., Jenkins L., et al. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 2007, 64:1323-1329.
35. Heckman P.R., Wouters C., Prickaerts J. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview. Curr Pharm Des 2014, 21:317-331.
36. Hescham S., Lim L.W., Jahanshahi A., et al. Deep brain stimulation in dementia-related disorders. Neurosci Biobehav Rev 2013, 37:2666-2675.
37. Hongpaisan J., Sun M.K., Alkon D.L. PKC epsilon activation prevents synaptic loss, Abeta elevation, and cognitive deficits in Alzheimer's disease transgenic mice. J Neurosci 2011, 31:630-643.
38. Jelic V., Kivipelto M., Winblad B. Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatr 2006, 77:429-438.
39. Kaasinen V., Nagren K., Jarvenpaa T., et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol 2002, 22:615-620.
40. Kadir A., Darreh-Shori T., Almkvist O., et al. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging 2008, 29:1204-1217.
41. Kuhl D.E., Minoshima S., Frey K.A., et al. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 2000, 48:391-395.
42. Leber P. Guidelines for the clinical evaluation of antidementia drugs: first draft 1990, USFDA, US Food and Drug Administration, New Canaan, CT.
43. Li W., Antuono P.G., Xie C., et al. Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment. NeuroImage 2012, 60:1083-1091.
44. Mega M.S., Cummings J.L., O'Connor S.M., et al. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease. Neuropsychiatr Neuropsychol Behav Neurol 2001, 14:63-68.
45. Mega M.S., Dinov I.D., Porter V., et al. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Arch Neurol 2005, 62:721-728.
46. Mohs R.C., Doody R.S., Morris J.C., et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001, 57:481-488.
47. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
48. Nardone R., Tezzon F., Holler Y., et al. Transcranial magnetic stimulation (TMS)/repetitive TMS in mild cognitive impairment and Alzheimer's disease. Acta Neurol 2014, 129:351-366.
49. Olde Rikkert M.G., Verhey F.R., Blesa R., et al. Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study. J Alzheimers Dis 2014, 44:471-480.
50. Olivares D., Deshpande V.K., Shi Y., et al. N-methyl d-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr Alzheimer Res 2012, 9:746-758.
51. Parsons C.G., Danysz W., Dekundy A., et al. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. Neurotox Res 2013, 24:358-369.
52. Pehrson A.L., Leiser S.C., Gulinello M., et al. Treatment of cognitive dysfunction in major depressive disorder-a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. Eur J Pharmacol 2014, 753:19-31.
53. Reger M.A., Henderson S.T., Hale C., et al. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 2004, 25:311-314.
54. Rosen W.G., Mohs R.C., Davis K.L. A new rating scale for Alzheimer's disease. Am J Psychiatr 1984, 141:1356-1364.
55. Rountree S.D., Atri A., Lopez O.L., et al. Effectiveness of antidementia drugs in delaying Alzheimer's disease progression. Alzheimers Dement 2013, 9:338-345.
56. Russell C., Rahman A., Mohammed A.R. Application of genomics, proteomics and metabolomics in drug discovery, development and clinic. Ther Deliv 2013, 4:395-413.
57. Salloway S., Sperling R., Fox N.C., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014, 370:322-333.
58. Scheltens P., Twisk J.W., Blesa R., et al. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J Alzheimers Dis 2012, 31:225-236.
59. Schmitt F.A., Ashford W., Ernesto C., et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997, 11(Suppl 2):S51-S56.
60. Schneider L.S., Sano M. Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement 2009, 5:388-397.
61. Schneider L.S., Olin J.T., Doody R.S., et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997, 11(Suppl 2):S22-S32.
62. Shevtsova E.F., Vinogradova D.V., Kireeva E.G., et al. Dimebon attenuates the Abeta-induced mitochondrial permeabilization. Curr Alzheimer Res 2014, 11:422-429.
63. Shinotoh H., Aotsuka A., Fukushi K., et al. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology 2001, 56:408-410.
64. Sperling R.A., Jack C.R., Black S.E., et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011, 7:367-385.
65. Spires-Jones T.L., Hyman B.T. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron 2014, 82:756-771.
66. Sultzer D.L., Melrose R.J., Harwood D.G., et al. Effect of memantine treatment on regional cortical metabolism in Alzheimer's disease. Am J Geriatr Psychiatr 2010, 18:606-614.
67. Swerdlow R.H., Burns J.M., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta 2014, 1842:1219-1231.
68. Thomsen M.S., Hansen H.H., Timmerman D.B., et al. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des 2010, 16:323-343.
69. Tong L.M., Djukic B., Arnold C., et al. Inhibitory interneuron progenitor transplantation restores normal learning and memory in ApoE4 knock-in mice without or with Abeta accumulation. J Neurosci 2014, 34:9506-9515.
70. Tsukada H., Nishiyama S., Fukumoto D., et al. Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: functional imaging of the conscious monkey brain using animal PET in combination with microdialysis. Synapse 2004, 52:1-10.
71. Guidance for industry: Alzheimer's disease: developing drugs for the treatment of early stage disease 2013, US Food and Drug Administration, USFDA, Washington, DC.
72. Weinreb O., Amit T., Bar-Am O., et al. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets 2012, 13:483-494.
73. Whitehouse P.J. The cholinergic deficit in Alzheimer's disease. J Clin Psychiatr 1998, 59(Suppl 13):19-22.
74. Wilkinson D., Fox N.C., Barkhof F., et al. Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. J Alzheimers Dis 2012, 29:459-469.
75. Wilkinson D., Windfeld K., Colding-Jorgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2014, 13:1092-1099.
76. Wilkosz P.A., Seltman H.J., Devlin B., et al. Trajectories of cognitive decline in Alzheimer's disease. Int Psychogeriatr 2010, 22:281-290.
77. Winblad B., Cummings J., Andreasen N., et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatr 2007, 22:456-467.
78. Xiang G.Q., Tang S.S., Jiang L.Y., et al. PPARgamma agonist pioglitazone improves scopolamine-induced memory impairment in mice. J Pharm Pharmacol 2012, 64:589-596.
79. Yarchoan M., Arnold S.E. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 2014, 63:2253-2261.
80. Youdim M.B. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Curr Alzheimer Res 2006, 3:541-550.
81. Yu C.J., Liu W., Chen H.Y., et al. BACE1 RNA interference improves spatial memory and attenuates Abeta burden in a streptozotocin-induced tau hyperphosphorylated rat model. Cell Biochem Funct 2014, 32:590-596.
82. Zaidel L., Allen G., Cullum C.M., et al. Donepezil effects on hippocampal and prefrontal functional connectivity in Alzheimer's disease: preliminary report. J Alzheimers Dis 2012, 31(Suppl 3):S221-S226.
83. Zemek F., Drtinova L., Nepovimova E., et al. Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf 2014, 13:759-774.